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Achilles’ Heel of Statins?
Differences Between the New
Cholesterol Treatment Guidelines
and Everyday Clinical PracticeThe American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) welcomes letters to inform its ongoing
work and encourages such correspondence about its guidelines.
Because the ACCF/AHA guideline development process is
rigorous and involves several layers of review by the writing com-
mittee, external peer reviewers, and participating organizations in
the document, it cannot respond to each issue raised after a
guideline has been published. The information, however, is for-
warded to the writing committee chair and oversight task forcefor review. If any issue is deemed by the ACCF/AHA to affect
patient safety, it will be considered immediately. Otherwise, the
information will be considered during the next update or revision
of the guideline.The American College of Cardiology
http://dx.doi.org/10.1016/j.jacc.2014.02.532Carotid Intima-Media
Thickness and Cardiovascular
Disease Risk Prediction
The 2013 American College of Cardiology and American Heart
Association guideline on the assessment of cardiovascular risk
gave a class III recommendation for carotid intima-media thick-
ness (IMT) testing (1). This assessment was based on an inac-
curate description of the clinical use of carotid IMT testing by
focusing only on the common carotid artery (CCA). The Amer-
ican Society of Echocardiography consensus statement (2) and
others have speciﬁed that carotid ultrasound for cardiovascular
disease risk prediction should be based on a thorough scan of the
carotid arteries for the presence of plaques, followed by mea-
surement of CCA IMT. This is because the presence and extent
of carotid plaque, which occurs predominantly in the carotid
bifurcation and internal carotid artery, rather than the CCA, are
independent predictors of future cardiovascular disease events
and in observational studies have performed better than CCA IMT
alone (3). The consensus statement, which has been widely adop-
ted, speciﬁcally stipulates that measuring CCA IMT without
considering plaque presence is not sufﬁcient; however, the evidence
that provided the working group with the “strongest evidence” for
its class III recommendation was a meta-analysis based solely on
CCA IMT (4).
The working group raised important concerns about stan-
dardization and measurement issues, but the clinical use of this
test has been standardized for more than 5 years (2) and has
published appropriate use criteria (5), and its reproducibility
is excellent, even in inexperienced hands. We believe that a
class IIb recommendation would be more appropriate, on the
basis of the test characteristics of carotid IMT plus plaque
scanning.
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Healthy Elderly Subjects
What Is the Number Needed to Treat?I read with interest the paper by Savarese et al. (1) reporting the
results of a meta-analysis of the beneﬁts of statins in elderlysubjects without established cardiovascular (CV) disease. One of
the biggest questions facing clinical cardiology today is the deci-
sion regarding which individuals to treat with statins in primary
prevention. Because statins are not without adverse effects, we
have to be sure that the risk of harm does not outweigh the pre-
sumed beneﬁts.
In their meta-analysis, Savarese et al. (1) came to the conclusion
that statins signiﬁcantly reduce the incidence of myocardial
infarction (MI) and stroke but do not signiﬁcantly prolong survival
in the short-term. They believe their meta-analysis provides “ﬁrst-
time evidence that the beneﬁts of statins on major CV events ex-
tends to people 65 years without CV disease.”
MI occurred in 2.7% of subjects allocated to receive statins
compared with 3.9% of those receiving placebo during a mean
follow-up of 3.5 years. This ﬁnding corresponds to a relative risk
reduction of 39.4%. Stroke was reported in 2.1% of subjects ran-
domized to receive statins compared with 2.8% receiving placebo
during the same mean follow-up period. This ﬁnding corresponds
to a relative risk reduction of 23.8%.
The authors calculated that 24 patients needed to be treated for
1 year to prevent 1 MI and that 42 patients needed to be treated for
1 year to prevent 1 stroke. The authors repeat these numbers in the
ﬁnal section of the paper, where cost/beneﬁt evaluation of statin
treatment in elderly subjects is discussed.
It appears that the authors have made an erroneous calculation.
The annual MI rate was 1.1%, and the annual rate of stroke was
0.8% in patients allocated to receive placebo. Considering a relative
risk reduction of 39.4% and 23.8%, respectively, the absolute risk
reduction (ARR) for 1 year is approximately 0.43% for MI and
0.19% for stroke. The number needed to treat (NNT) is the inverse
of the ARR: NNT ¼ 100/ARR.
By using data from the paper, I have calculated that the
NNT for 1 year to prevent 1 MI and 1 stroke, respectively, may be
approximately 10 times higher than that reported by Savarese et al.
(1), given that NNT is constant over time. In my opinion, the most
appropriate approach would have been to report the NNT for the
mean follow-up of 3.5 years, which would have been approximately
83 to prevent 1 MI and 142 to prevent 1 stroke. This is the
approach most commonly used in similar studies.
The NNT is very important when assessing the efﬁcacy of
statin therapy. It is therefore essential that the authors do a recal-
culation of their data and report the correct NNT numbers. They
may also have to reconsider the main conclusions of their meta-
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